Physician profile
Raviteja Guddeti
NPI 1891101986
$67,964.32
in general payments reported to CMS, 2019-2025
17 companies · $3,947 in 2025
The $3,947 reported for 2025 was more than what 80% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $337 · 2021: $190 · 2022: $229 · 2023: $631 · 2024: $63K · 2025: $3,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $60K · Travel and Lodging: $2,954 · Consulting Fee: $2,400 · Food and Beverage: $1,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $60,000.00 |
| Travel and Lodging | $2,954.23 |
| Consulting Fee | $2,400.00 |
| Food and Beverage | $1,728.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23,783.21 | 2022-2025 | Navitor, Triclip, Mitraclip |
| Medtronic, INC. | $21,072.28 | 2021-2024 | Corevalve Evolut R |
| Boston Scientific Corporation | $20,259.15 | 2019-2025 | Avvigo Guidance System, Watchman, Comet |
| Edwards Lifesciences Corporation | $1,586.85 | 2020-2024 | Pascal |
| Teleflex LLC | $368.09 | 2023 | Trapliner, Turnpike |
| Jenavalve Technology, INC. | $175.25 | 2025 | |
| Cardiovascular Systems INC. | $171.33 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $146.43 | 2022-2024 | Lifevest |
| Abiomed | $126.21 | 2022 | |
| Amgen INC. | $68.78 | 2023-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.17 | 2021-2023 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $36.59 | 2022-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $32.29 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $27.86 | 2021-2022 | |
| Philips North America LLC | $22.14 | 2024 | (Br0) Coronary Atherectomy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | $21.62 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $20.07 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raviteja Guddeti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.